It did well in using COM701 as a monotherapy and triple combination regimen [PVRIG + TIGIT + PD-1] in targeting such PROC patients and thus, that's why it was able to shift to relapsed PSOC ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for ...